Daily Stock Opinions and Ratings

Opinions

Martin Hubbes, CFA Angiotech Pharmaceuticals ANP-T TOP PICK Aug 24, 2001

Expects health services to lead the market. More angioplasty due to aging population.

Martin Hubbes, CFA

Unknown

Unlock Rating

$87.850

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.

COMMENT

Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.

DON'T BUY

They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.

SELL

A one trick pony with its coated stent. There is lots of controversy on drug coated stents.

SELL

The whole market is going up, and this one is going down. Let someone else own it.

HOLD

Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.

COMMENT

The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.

DON'T BUY

Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.

BUY ON WEAKNESS

(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.

DON'T BUY

What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.

Most Recent Experts

Mike Philbrick

ReSolve Asset Management

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Martin Hubbes, CFA Angiotech Pharmaceuticals ANP-T TOP PICK Aug 24, 2001

You might be interested:

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Angiotech Pharmaceuticals(ANP-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Mike Philbrick

Stockchase Insights

The Panic-Proof Portfolio (Stockchase Research)

Jim Cramer - Mad Money

The Weekly Buzzing Stocks by Billy Kawasaki